Enzalutamide: new second-line treatment for prostate cancer

Enzalutamide is a new second-line treatment for castration-resistant prostate cancer. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Heather Payne discusses its place in treatment.

Enzalutamide new second line treatment for prostate cancer

Add yours ↓
Web design and marketing agency Leamington Spa